ANEB Company Profile and Key Details

Anebulo Pharmaceuticals, Inc. generated EPS of -$0.19 over the past year. Five-year average earnings growth is -102.33%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at $nan. Next year's EPS is expected at -$23.65. Anebulo Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended February 12, 2026, missed forecasts by -61.54%. The prior quarter beat by -58.33%. Over the last six quarters, Apple has recorded several small beats. These include 60.0% in November 13, 2024.

Short-term trend indicators are bullishly aligned (SMA20 -28.99%, SMA50 -57.85%, SMA200 -76.66%). The stock’s 14-day RSI is 20.62 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.39% below its high and over 5.15% above its low. Average 10-day trading volume of 382.38 shares is slightly above the 3-month average of 274.22, indicating heightened recent market interest.

Anebulo Pharmaceuticals, Inc. has 40.78 million shares outstanding. The public float is 24.13 million shares, elevated short interest at 2.20% of float. This equals 146.37 thousand shares. The short ratio is 1.5 days. Institutional investors hold 0.0% of the float. Insiders own 40.84%.

Anebulo Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.34. This means the shares are trading near this model’s fair value.

Anebulo Pharmaceuticals, Inc. trades at a P/E ratio of -1.67, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.68 suggesting the stock is closer to book value. The P/FCF stands at -2.27, also below market averages.

Anebulo Pharmaceuticals, Inc. (OTC:ANEB) closed at $0.33 USD, gaining $0.03 (8.33%) from the previous close of $0.30. The stock is currently mid-range between its 52-week high and low $0.00 and $2.85. With a market capitalization of about $13.26 million, Anebulo Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.83). Key stats such as the average daily volume over the past year has been around 252.00 shares, volume is running light vs its 52-week average. Headquartered in Lakeway, TX, Anebulo Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard Anthony Cunningham, the company employs approximately 3 people and listed since May 07, 2021. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.

Our AI price prediction model suggests that Anebulo Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.69%, with price expected at $0.30 by October 07, 2026, within a range of $0.27 to $0.34 3-Month Outlook: Projected fall of -75.38%, reaching $0.08 by December 22, 2026, with a range of $0.00 to $0.16. 1-Year Outlook: Projected loss of -75.38%, with price at $0.08 by September 23, 2027, within a range of $0.00 to $0.00.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares are flat 7.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Anebulo Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -1.67. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $7.25, suggesting 2130.77% upside. Our AI forecast model points to short-term weakness (-7.69% over two weeks), a medium-term fall (-75.38% over three months), and a longer-term loss (-75.38% over one year), with expected trading ranges indicating moderate volatility.